<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810975</url>
  </required_header>
  <id_info>
    <org_study_id>2020-12-15</org_study_id>
    <nct_id>NCT04810975</nct_id>
  </id_info>
  <brief_title>Strength Training Effects on Musculoskeletal Health</brief_title>
  <acronym>Muscle:Time</acronym>
  <official_title>Strength Training Effects on Musculoskeletal Health, Melatonin, Rest-activity Rhythms and Quality of Life: Muscle:Time Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duquesne University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jaquish Biomedical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duquesne University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective here is to assess the efficacy of variable resistance muscle training on bone,&#xD;
      sleep parameters and quality of life in healthy populations of men and women age 30 or older.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 8, 2021</start_date>
  <completion_date type="Anticipated">June 8, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lean Body Mass</measure>
    <time_frame>0-6 months</time_frame>
    <description>Muscle measurements and fat composition will be assessed by Tanita at baseline (month 0) and month 6. Muscle mass, expressed as percentage change from baseline to month 6, will be compared within and between groups at 6 mos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Circumference</measure>
    <time_frame>0-6 months</time_frame>
    <description>Total body circumference will be measured by Army Body Fat Calculator at baseline (month 0) and month 6. Body circumference, expressed as percentage change from baseline to month 6, will be compared within and between groups at 6 mos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional test 1 to assess musculoskeletal strength</measure>
    <time_frame>0-6 months</time_frame>
    <description>Functional-Timed Up and Go Test will assess musculoskeletal strength at baseline (month 0) and month 6. Timed up-and-go times, expressed as change from baseline to month 6, will be compared within and between groups at 6 mos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional test 2 to assess musculoskeletal strength</measure>
    <time_frame>0-6 months</time_frame>
    <description>Functional-Sit-to-Stand Test will assess musculoskeletal strength at baseline (month 0) and month 6. Functional Sit-to-stand times, expressed as change from baseline to month 6, will be compared within and between groups at 6 mos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marker activity-bone resorption</measure>
    <time_frame>0-6 months</time_frame>
    <description>Urinary CTx levels will be assessed at baseline (month 0) and month 6. The Effect of muscle strengthening on changes in Human Type 1 Collagen C-telopeptide (CTx) levels from baseline to month 6, will be compared within and between groups at 6 mos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marker activity-bone formation</measure>
    <time_frame>0-6 months</time_frame>
    <description>Urinary P1NP levels will be assessed at baseline (month 0) and month 6. The Effect of muscle strengthening on changes in Human Procollagen Type 1 Intact N-terminal Propeptide (Total P1NP) levels from baseline will be compared within and between groups at 6 mos.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of bone resorption to bone formation</measure>
    <time_frame>0-6 months</time_frame>
    <description>Urinary CTx:P1NP levels will be assessed at baseline (month 0) and month 6. The effect of muscle strengthening on changes in the ratio of CTx to P1NP will be assessed at baseline and then compared within and between groups at month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hormone levels-Testosterone</measure>
    <time_frame>0-6 months</time_frame>
    <description>Urinary testosterone levels will be assessed at baseline (month 0) and month 6. The effect of muscle strengthening on changes in testosterone levels will be assessed at baseline and then compared within and between groups at month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hormone levels-Cortisol</measure>
    <time_frame>0-6 months</time_frame>
    <description>Urinary cortisol levels will be assessed at baseline (month 0) and month 6. The effect of muscle strengthening on changes in cortisol levels will be assessed at baseline and then compared within and between groups at month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Marker</measure>
    <time_frame>0-6 months</time_frame>
    <description>Urinary C-reactive protein levels will be assessed at baseline (month 0) and then at month 6. The effect of muscle strengthening on changes in CRP will be assessed at baseline and then compared within and between groups at month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rest-activity rhythms</measure>
    <time_frame>0-6 months</time_frame>
    <description>Rest activity rhythms will be assessed at baseline (month 0) and month 6. The effect of muscle strengthening on changes in rest-activity rhythms will be assessed at baseline and then compared within and between groups at month 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin</measure>
    <time_frame>0-6 months</time_frame>
    <description>Salivary Melatonin levels will be assessed at baseline (month 0) and month 6. The effect of muscle strengthening on changes in melatonin rhythms will be assessed at baseline and then compared within and between groups at month 6.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Musculoskeletal Diseases</condition>
  <arm_group>
    <arm_group_label>The effect of exercise A on musculoskeletal health</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>The effect of exercise B on musculoskeletal health</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Muscle Strength Training</intervention_name>
    <description>Strength training occurring specific exercise regimens using Exercise Equipment A or B</description>
    <arm_group_label>The effect of exercise A on musculoskeletal health</arm_group_label>
    <arm_group_label>The effect of exercise B on musculoskeletal health</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  30 years or older (males or females)&#xD;
&#xD;
          -  Baseline strength (e.g., can lift an office chair with no problems)&#xD;
&#xD;
          -  Be willing to participate in a 6-month RCT&#xD;
&#xD;
          -  Be willing to conduct daily muscle training exercises&#xD;
&#xD;
          -  Be willing to maintain a food diary&#xD;
&#xD;
          -  Be willing to consume ~2.2g/kg body weight daily&#xD;
&#xD;
          -  Be willing to submit specimens and conduct tests 3 times over 6 months (0, 3 and 6&#xD;
             months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those who consume vegan or vegetarian diets&#xD;
&#xD;
          -  people with conditions like hypertension and uncontrolled non-medicated blood&#xD;
             pressure; cardiovascular disease/heart failure (e.g., arrhythmias, unstable angina,&#xD;
             congestive heart failure)&#xD;
&#xD;
          -  COPD&#xD;
&#xD;
          -  drugs that may increase fall risk or make dizzy (e.g., antidepressants, anti-seizure&#xD;
             drugs)&#xD;
&#xD;
          -  muscle disease (e.g., myasthenia gravis, myopathy, myositis)&#xD;
&#xD;
          -  active hernia&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  muscle atrophy (e.g., Duchenne muscular dystrophy (DMD), Becker muscular dystrophy&#xD;
             (BMD), ALS)&#xD;
&#xD;
          -  neuro degenerative disease&#xD;
&#xD;
          -  limited mobility&#xD;
&#xD;
          -  those who consume proteins supplements.&#xD;
&#xD;
          -  Individuals who have implanted pacemakers or defibrillators&#xD;
&#xD;
          -  People who suffer from: Marfan syndrome, migraine, hyperparathyroidism, metastatic&#xD;
             bone disease, multiple myeloma&#xD;
&#xD;
          -  chronic steroid use&#xD;
&#xD;
          -  individuals with restrictions to movement and exercise&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Witt-Enderby, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duquesne University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Witt-Enderby, Ph.D.</last_name>
    <phone>412-396-4296</phone>
    <email>wittp@duq.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Divya Shetty</last_name>
    <phone>412-880-7250</phone>
    <email>shettyd@duq.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duquesne University</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

